Current and emerging new treatment strategies for mantle cell lymphoma

Leukemia and Lymphoma

Volumn 54, Issue 5, 2013, Pages 912-921

  Humala, Karem ^a   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Mantle cell lymphoma; Targeted therapy

Indexed keywords

B LYMPHOCYTE ANTIGEN; BENDAMUSTINE; BORTEZOMIB; CYCLINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EVEROLIMUS; JANUS KINASE; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PREDNISONE; RAPAMYCIN; RITUXIMAB; TEMSIROLIMUS; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CELL CYCLE; CLINICAL FEATURE; CLINICAL PROTOCOL; ELDERLY CARE; EVENT FREE SURVIVAL; HUMAN; INFECTION; MANTLE CELL LYMPHOMA; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; THROMBOCYTOPENIA;

AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; MOLECULAR TARGETED THERAPY; RECURRENCE; TREATMENT OUTCOME;

EID: 84876103476     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.726719     Document Type: Review

References (88)

1. Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019-5032.
2. Ferrer A, Salaverria I, Bosch F, et al. Leukemic involvement is a common feature in mantle cell lymphoma. Cancer 2007; 109: 2473-2480.
3. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007; 7: 750-762.
4. Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011;117:26-38.
5. Dreyling M, Hoster E, Bea S, et al. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma (MCL): minutes of the 9th European MCL Network conference. Leuk Lymphoma 2010; 51: 1612-1622.
6. Salaverria I, Zettl A, Bea S, et al. Specif c secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007;25:1216-1222.
7. Kridel R, Meissner B, Rogic S, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 2012;119:1963-1971.
8. Fernandez V, Salamero O, Espinet B, et al. Genomic and gene expression prof ling defines indolent forms of mantle cell lymphoma. Cancer Res 2010; 70: 1408-1418.
9. Ek S, Dictor M, Jerkeman M, et al. Nuclear expression of the non B-cell lineage Sox11 transcription factor identif es mantle cell lymphoma. Blood 2008; 111: 800-805.
10. Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specif c for mantle cell lymphoma and identif es the cyclin D1-negative subtype. Haematologica 2009;94:1555-1562.
11. Schafel R, Hedvat CV, Teruya-Feldstein J, et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol 2010;21:133-139.
12. Teodorovic I, Pittaluga S, Kluin-Nelemans JC, et al. Effcacy of four Different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995; 13: 2819-2826.
13. Argatof LH, Connors JM, Klasa RJ, et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997;89:2067-2078.
14. Zucca E, Roggero E, Pinotti G, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6: 257-262.
15. Hiddemann W, Unterhalt M, Herrmann R, et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 1998; 16: 1922-1930.
16. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009;27:511-518.
17. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009; 27: 1209-1213.
18. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013-7023.
19. Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010; 150: 200-208.
20. Epner EM, Unger J, Miller T, et al. A multi center trial of hyperCVAD+rituxan in patients with newly diagnosed mantle cell lymphoma. Blood 2007;110(Suppl. 1): Abstract 387.
21. Andersen NS, Pedersen L, Elonen E, et al. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol 2003;71:73-80.
22. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687-2693.
23. Lefrere F, Delmer A, Suzan F, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002;16:587-593.
24. Lefrere F, Delmer A, Levy V, et al. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 2004; 89: 1275-1276.
25. Delarue R, Haioun C, Ribrag V, et al. RCHOP and RDHAP followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): final results of a phase II study from the GELA. Blood 2008; 112(Suppl. 1): Abstract 581.
26. Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood 2010; 116(Suppl. 1): Abstract 110.
27. LaCasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 2012;119:2093-2099.
28. Kluin-Nelemans JC, Hoster E, Walewski J, et al. R-CHOP versus R-FC followed by maintenance with rituximab versus interferon-alfa: outcome of the first randomized trial for elderly patients with mantle cell lymphoma. Blood 2011; 118(Suppl. 1): Abstract 439.
29. Kahl BS, Longo WL, Eickhof JC, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006;17:1418-1423.
30. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 2010;116:106-114.
31. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26:204-210.
32. Roue G, Lopez-Guerra M, Milpied P, et al. Bendamustine is effective in p53-def cient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res 2008; 14:6907-6915.
33. Rummel MJ, Heine K, Bodenstein H, et al. Ef cacy and safety of bendamustine and rituximab in the treatment of indolent and mantle cell lymphomas in older patients. J Clin Oncol 2008; 26(Suppl.): Abstract 8572.
34. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009;114(Suppl. 1): Abstract 405.
35. Jerkeman M, Kolstad A, Laurell A, et al. Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: results from the phase I portion of the Nordic Lymphoma Group MCL4 (LENA-BERIT) trial. Blood 2011; 118(Suppl. 1): Abstract 2700.
36. Magni M, Di Nicola M, Carlo-Stella C, et al. Safety, tolerability and activity of ofatumumab, bendamustine and dexamethasone combination as first-line treatment of mantle-cell lymphoma in the elderly: a multicenter study. Blood 2011; 118(Suppl. 1): Abstract 1647.
37. Visco C, Zambello R, Paolini R, et al. Rituximab, bendamustine and cytarabine (R-BAC) is a very active regimen in patients with mantle cell lymphoma not eligible for intensive chemotherapy or autologous transplant. Blood 2011; 118(Suppl. 1): Abstract 2677.
38. Ghielmini M, Schmitz SF, Cogliatti S, et al. effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005;23:705-711.
39. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867-4874.
40. Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009;20:520-525.
41. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-684.
42. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667-675.
43. Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690-697.
44. Kahl BS, Li H, Smith MR, et al. The VcR-CVAD regimen produces a high complete response rate in untreated mantle cell lymphoma (MCL): first analysis of E1405- A phase II study of VcR-CVAD with maintenance rituximab for MCL. Blood 2009; 114(Suppl. 1): Abstract 1661.
45. Perez-Galan P, Mora-Jensen H, Weniger MA, et al. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic diferentiation. Blood 2011;117:542-552.
46. Peponi E, Drakos E, Reyes G, et al. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 2006;169:2171-2180.
47. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005;23:5347-5356.
48. Ansell SM, Inwards DJ, Rowland KM Jr, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008; 113: 508-514.
49. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822-3829.
50. Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 2011;12:361-368.
51. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473-4479.
52. Warsch S, Hosein PJ, Maeda LS, et al. A retrospective study evaluating the ef cacy and safety of bendamustine in the treatment of mantle cell lymphoma. Leuk Lymphoma 2012;53:1299-1305.
53. Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011;117:2807-2812.
54. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009; 69: 7347-7356.
55. Gaidarova S, Corral LG, Glezer E, et al. Treatment of MCL cells with combined rituximab and lenalidomide enhances NK-mediated synapse formation and cell killing. Blood 2009; 114(Suppl. 1): Abstract 1687.
56. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009; 145: 344-349.
57. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011;22:1622-1627.
58. Zaja F, De Luca S, Vitolo U, et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 2012; 97: 416-422.
59. Wang M, Zhang L, Fayad L, et al. Lenalidomide and rituximab are a promising combination in vitro, in vivo preclinically and in a phase I/II clinical trial in relapsed/refractory mantle cell lymphoma. Blood 2008; 112(Suppl. 1): Abstract 3058.
60. Robinson SP, Schmitz N, Taghipour G, et al. Reduced intensity allogeneic stem cell transplantation for mantle cell lymphoma is associated with substantial late transplant related mortality and a poor outcome in patients with chemoresistant disease. Blood 2004; 104(Suppl. 1): Abstract 2260.
61. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003;21:4407-4412.
62. Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117:591-594.
63. Kahl B, Byrd JC, Flinn IW, et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, in patients with relapsed or refractory non-Hodgkin lymphoma. Blood 2010;116(Suppl. 1): Abstract 1777.
64. Garlich JR, Becker MD, Shelton CF, et al. Phase I study of novel prodrug dual PI3K/mTOR inhibitor SF1126 in B-cell malignancies. Blood 2010; 116(Suppl. 1): Abstract 1783.
65. Friedman DR, Davis PH, Lanasa MC, et al. Pre-clinical and interim results of a phase II trial of perifosine in patients with relapsed or refractory chronic Lymphocytic leukemia (CLL). Blood 2010; 116(Suppl. 1): Abstract 1842.
66. Gills JJ, Dennis PA: Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 2009; 11: 102-110.
67. O'Connor OA, Popplewell L, Winter JN, et al. PILLAR-1: preliminary results of a phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to bortezomib. Blood 2010;116(Suppl. 1): Abstract 3963.
68. Renner C, Zinzani P, Gressin R, et al. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012;97:1085-1091.
69. Gupta M, Hendrickson AW, Han JJ, et al. Dual inhibition of mTORC1/mTORC2 induces apoptosis of mantle cell lymphoma by preventing Rictor mediated AKTS473 phosphorylation by potentiating AKT2-PHLPP1 association. Blood 2010;116(Suppl. 1): Abstract 772.
70. Boyd RS, Jukes-Jones R, Walewska R, et al. Protein prof ling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. Mol Cell Proteomics 2009; 8: 1501-1515.
71. Rinaldi A, Kwee I, Taborelli M, et al. Genomic and expression prof ling identif es the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol 2006;132:303-316.
72. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-2585.
73. Morschhauser F, Seymour JF, Kluin-Nelemans HC, et al. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol 2008; 19: 247-253.
74. Fowler N, Sharman JP, Smith SM, et al. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from a phase I study. Blood 2010; 116(Suppl. 1): Abstract 964.
75. Wang L, Martin P, Blum KA, et al. The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. Blood 2011; 118(Suppl. 1): Abstract 442.
76. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009; 8: 547-566.
77. Kouroukis CT, Belch A, Crump M, et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:1740-1745.
78. Lin TS, Blum KA, Fischer DB, et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 2010;28:418-423.
79. Manohar SM, Rathos MJ, Sonawane V, et al. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. Leuk Res 2011; 35: 821-830.
80. Santo L, Vallet S, Hideshima T, et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene 2010;29:2325-2336.
81. Squires MS, Cooke L, Lock V, et al. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol Cancer Ter 2010;9: 920-928.
82. Marzec M, Kasprzycka M, Lai R, et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 2006; 108: 1744-1750.
83. Constantinescu SN, Girardot M, Pecquet C. Mining for JAK-STAT mutations in cancer. Trends Biochem Sci 2008;33:122-131.
84. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002;20:1288-1294.
85. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984-1992.
86. Smith MR, Li H, Gordon L, et al. Phase II study of R-CHOP followed by (90)Y-ibritumomab tiuxetan in untreated mantle cell lymphoma (MCL): 5 year follow-up of Eastern Cooperative Oncology Group E1499. Ann Oncol 2011; 22: 86-87.
87. Herold M, Dolken G, Fiedler F, et al. Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab. Ann Hematol 2003;82:77-79.
88. Younes A, Fanale MA, McLaughlin P, et al. Phase I study of a novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. Blood 2010;116(Suppl. 1): Abstract 2830.